PDL BioPharma, Inc. Ending Cash

Ending Cash of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Ending Cash growth rates and interactive chart.


Highlights and Quick Summary

  • Ending Cash for the quarter ending June 29, 2020 was $4.45 Million (a -96.76% decrease compared to previous quarter)
  • Year-over-year quarterly Ending Cash decreased by -109.27%
  • Annual Ending Cash for 2019 was $193 Million (a -50.97% decrease from previous year)
  • Annual Ending Cash for 2018 was $395 Million (a -25.16% decrease from previous year)
  • Annual Ending Cash for 2017 was $527 Million (a 258.31% increase from previous year)
  • Twelve month Ending Cash ending June 29, 2020 was $-6.97 Million (a -56.59% decrease compared to previous quarter)
  • Twelve month trailing Ending Cash decreased by -102.42% year-over-year
Trailing Ending Cash for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-6.97 Million $-16.1 Million $193 Million $288 Million
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Ending Cash of PDL BioPharma, Inc.

Most recent Ending Cashof PDLI including historical data for past 10 years.

Interactive Chart of Ending Cash of PDL BioPharma, Inc.

PDL BioPharma, Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $4.45 $137.37
2019 $-100.82 $-47.97 $-4.64 $346.89 $193.45
2018 $-6.39 $5.33 $-9.43 $405.08 $394.59
2017 $17.18 $160.66 $35.1 $314.33 $527.27
2016 $40.56 $-9.26 $-174.8 $290.65 $147.15
2015 $-8.97 $-64.21 $-124.6 $416.67 $218.88
2014 $9.77 $67.08 $-119.51 $334.04 $291.38
2013 $-225.29 $68.12 $69.28 $182.19 $94.3
2012 $-1.38 $-51.92 $43.14 $141.37 $131.21
2011 $11.41 $-10.89 $41.31 $126.71 $168.54
2010 $11.09 $-10.83 $-108.36 $211.57

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.